• Quizartinib (AC220): Reading FLT3 Assay Endpoints

  2026-09-25

  Quizartinib (AC220) is a potent FLT3 inhibitor, but a useful AML experiment depends on distinguishing target inhibition from downstream cell effects. This article presents an endpoint-first framework for interpreting FLT3 assays and draws a carefully bounded methods insight from research on norovirus protein secretion.

• Protease Inhibitor Cocktail for Plant Extracts

  2026-09-25

  Learn when protein degradation inhibition can improve plant-lysate readouts—and why it should be applied after, not during, live-cell viability assays. This scenario-based guide explains practical use and limitations of Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1011.

• MHY1485: mTOR Activator Workflows for Autophagy

  2026-09-24

  Use MHY1485 to probe how mTOR activation relates to autophagy, with a workflow that distinguishes pathway engagement from blocked autophagosome clearance. Practical guidance covers stock handling, dose-and-time pilots, uveal melanoma mechanism studies, and a separate ovarian follicle research application.

• Flumequine: Choosing the Right Drug-Response Readout

  2026-09-24

  Flumequine is a DNA topoisomerase II inhibitor for studying how enzyme perturbation affects cell growth and survival. This guide connects its mechanism to a key assay-design principle: proliferation arrest and cell killing are distinct outcomes and should be measured accordingly.

• Rotenone, Redox Signaling, and Assay Interpretation

  2026-09-23

  Rotenone is a mitochondrial Complex I inhibitor used to study bioenergetic stress, apoptosis, and neurodegeneration. This guide connects rotenone experiment design with new DPP9–KEAP1 findings while distinguishing established evidence from testable hypotheses.

• From Fluorescent Reporter to Translational mRNA Insight

  2026-09-23

  A mechanistic and strategic guide to using EZ Cap™ EGFP mRNA (5-moUTP) as a reporter for evaluating mRNA delivery, translation, stability, innate immune activation, and translational delivery platforms.

• MK-1775: Wee1 Kinase Inhibitor Workflow

  2026-09-22

  Build more informative checkpoint-abrogation experiments with MK-1775 by pairing Wee1 target engagement with separate measurements of growth inhibition and cell death. This workflow helps distinguish direct cytotoxicity from sensitization of p53-deficient tumor cells to DNA-damaging agents.

• CUDC-907: Dual PI3K and HDAC Workflow

  2026-09-22

  CUDC-907 (SKU A4097) provides a research tool for coordinated interrogation of PI3K and HDAC signaling in cancer cell workflows. It is intended for controlled laboratory research, not diagnostic, therapeutic, or routine clinical use, and its dossier values should be independently verified in each model.

• MitMAB: A Precision Lens on Organoid Endocytosis

  2026-09-21

  MitMAB offers translational researchers a focused way to test dynamin-dependent vesicle uptake in physiologically relevant intestinal organoid models, extending milk-derived extracellular vesicle research beyond descriptive uptake assays.

• In Vivo CD19 CAR T Cells for Lupus

  2026-09-21

  A 2026 study developed CD5-targeted lipid nanoparticles that deliver CD19 CAR mRNA directly in vivo, generating functional CAR T cells without ex vivo manufacturing or lymphodepletion. In the MRL/lpr mouse model, this approach depleted pathogenic B-cell subsets, reduced autoimmune inflammation, and produced sustained disease remission, while leaving important translational and safety questions unresolved.

• Actinomycin D for mRNA Stability Workflows

  2026-09-20

  Actinomycin D converts transcriptional inhibition into a practical way to measure mRNA decay, cellular stress, and apoptosis. This guide adapts the approach to hypoxia-sensitive osteogenesis assays while showing how the same controls strengthen cancer research and DNA damage response studies.

• B. fragilis, Vagal Cholinergic Signaling, and Seizures

  2026-09-19

  Jia et al. identify a gut–vagus–brain cholinergic circuit through which Bacteroides fragilis suppresses seizures, linking colonic ChAT-positive cells, vagal transmission, and intestinal Lactobacillus enrichment. By combining mouse models, circuit manipulation, microbiota analysis, and a randomized pediatric trial, the study provides a mechanistic framework for microbiota-targeted treatment of refractory epilepsy.

• Cucurbitacin I (JSI-124) STAT3 Assay Workflow

  2026-09-18

  Build a mechanism-first workflow with Cucurbitacin I (JSI-124), linking rapid STAT3 target engagement to apoptosis, invasion, chemosensitivity, and xenograft endpoints. The strategy also adapts the modular logic of human SAN-plexus assembloids without confusing cardiac model innovation with cancer pharmacology evidence.

• Wogonin, Macrophage Polarization, and Osteoarthritis

  2026-09-18

  A 2025 Phytomedicine study shows that wogonin alleviates experimental osteoarthritis by regulating macrophage polarization and inflammatory signaling through the LSD1–p65 axis. Its combination of DMM modeling, transcriptomics, CRISPR-edited macrophages, and joint-tissue analysis provides a mechanistic framework for studying immune–cartilage–bone crosstalk.

• Probenecid Workflows for Transporter and T-Cell Research

  2026-09-17

  Probenecid enables mechanism-aware studies of MRP-mediated drug efflux, pannexin-1 signaling, and neuroinflammatory injury. This workflow also shows how to use it cautiously as an exploratory perturbation alongside CD28–ARS2–PKM immunometabolism assays, without confusing transporter effects with validated T-cell splicing mechanisms.

8715 records 1/581 page Next 12345 下5页 Last page